Citius Pharmaceuticals, Inc. (CTXR): Nasdaq/NYSE listing notice — Citius Pharma receives Nasdaq delisting notice for bid price non-compliance

Citius Pharmaceuticals, Inc.

Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.
Not eligible for compliance period due to reverse stock split within prior year.
Plans to appeal by June 5, 2025 to stay suspension; delisting would start June 9 without appeal.
No assurance that Nasdaq will grant relief or that compliance can be regained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)

Exact text from the filing

May 29, 2025, Citius Pharmaceuticals, Inc. (the “Company”) received a determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market notifying the Company that, based upon the closing bid price of the Company’s common stock for the prior 33 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Letter states that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)

View on SEC.gov

3 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-049550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.